Clinical pharmacokinetics of imatinib mesylate

被引：0
作者：
Levêque, D
Maloisel, F
机构：
[1] Hop Hautepierre, F-67000 Strasbourg, France
[2] Inst Bacteriol, F-67000 Strasbourg, France
[3] Hop Civil, Dept Hematol & Oncol, F-67000 Strasbourg, France
来源：
IN VIVO | 2005年 / 19卷 / 01期
关键词：
imatinib mesylate; pharmacokinetics;
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The review presents the clinical pharmacokinetics of imatinib mesylate. Aspects regarding absorption, tissue distribution, elimination and kinetic interactions are also discussed.
引用
收藏
页码：77 / 84
页数：8
相关论文
共 50 条
[1]  
ABRAMS PL, 2004, P AN M AM SOC CLIN, V23, P147
[2]   High-throughput quantification of the anti-leukemia drug ST1571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry [J].
Bakhtiar, R ;
Lohne, J ;
Ramos, L ;
Khemani, L ;
Hayes, M ;
Tse, F .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 768 (02) :325-340
[3]   Quantification of the anti-leukemia drug ST1571 (Gleevec™) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry [J].
Bakhtiar, R ;
Khemani, L ;
Hayes, M ;
Bedman, T ;
Tse, F .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 28 (06) :1183-1194
[4]   Changes in plasma protein binding have little clinical relevance [J].
Benet, LZ ;
Hoener, BA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (03) :115-121
[5]   Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects [J].
Bolton, AE ;
Peng, B ;
Hubert, M ;
Krebs-Brown, A ;
Capdeville, R ;
Keller, U ;
Seiberling, M .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (02) :102-106
[6]   Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects [J].
Borg, C ;
Terme, M ;
Taïeb, J ;
Ménard, C ;
Flament, C ;
Robert, C ;
Maruyama, K ;
Wakasugi, H ;
Angevin, E ;
Thielemans, K ;
Le Cesne, A ;
Chung-Scott, V ;
Lazar, V ;
Tchou, I ;
Crépineau, F ;
Lemoine, F ;
Bernard, J ;
Fletcher, JA ;
Turhan, A ;
Blay, JY ;
Spatz, A ;
Emile, JF ;
Heinrich, MC ;
Mécheri, S ;
Tursz, T ;
Zitvogel, L .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (03) :379-388
[7]  
Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139
[8]   Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump [J].
Burger, H ;
van Tol, H ;
Boersma, AWM ;
Brok, M ;
Wiemer, EAC ;
Stoler, G ;
Nooter, K .
BLOOD, 2004, 104 (09) :2940-2942
[9]   Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug [J].
Capdeville, R ;
Buchdunger, E ;
Zimmermann, J ;
Matter, A .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) :493-502
[10]   Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study [J].
Champagne, MA ;
Capdeville, R ;
Krailo, M ;
Qu, WC ;
Peng, B ;
Rosamilia, M ;
Therrien, M ;
Zoellner, U ;
Blaney, SM ;
Bernstein, M .
BLOOD, 2004, 104 (09) :2655-2660
12345